Paul Thompson, PhD
Medical Director, CNS Translational Medicine at Mission Therapeutics
Location: Cambridge, United Kingdom
Dr. Paul Thompson received his first degree from University of Oxford in 1998 and completed a PhD in cell biology, part funded by GlaxoSmithKline. Subsequently, Dr. Thompson spent 12 years at GlaxoSmithKline, transitioning from translational laboratory research to clinical research, ultimately specializing in neurology translational medicine. After a 2.5-year clinical director role at ONO Pharmaceutical, working across multiple therapeutic areas, he joined Mission Therapeutics in June 2016 as their medical director in CNS (central nervous system; the brain and spinal cord) Translational Medicine. Dr. Thompson currently leads all CNS efforts within Mission Therapeutics and takes project leader responsibility for their lead CNS project, USP30 inhibitors. Dr. Thompson is a full member of the British Pharmacological Society, Society for Neuroscience, and the American Academy of Neurology.